LR-HEALTH-&-BEAUTY
7.6.2019 14:22:08 CEST | Business Wire | Press release
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir. Four months after the market launch and a sensational amount of sold 2.6 million* shots, the revolutionary product was awarded the German Brand Award 2019 yesterday. In competition with "Excellent Brands", the Elixir impressed the top-ranking jury in the "Beauty & Care" category as one of the best product brands in the industry. In addition, the Elixir also received the "Special Mention" distinction in the cross-industry category "Product of the Year", which the jury awards for special aspects in branding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005247/en/
Andreas Friesch, CEO of LR Health & Beauty, is very proud of receiving this award. "Being the 'Winner' of the German Brand Award 2019 is a wonderful recognition for a very special product development. With the LR LIFETAKT 5in1 Beauty Elixir, we demonstrate our extensive health and beauty know-how in a single product. It is a reflection of our spectrum of competence and bears - like most of our products - the 'Made in Germany' seal of quality. Furthermore, the award is a motivation to continue developing pioneering innovations in the future as well.”
Excellent Beautyfood: LR LIFETAKT 5in1 Beauty Elixir
The most successful product launch in the history of the company, the LR LIFETAKT 5in1 Beauty Elixir fulfills five beauty wishes at once: youthful appearance, clear skin, firm body, healthy hair and strong nails. With just one shot a day, it ensures radiant beauty from head to toe – thanks to the unique double-complex with the most important active ingredients for beauty from science and from the power of nature. The 5in1 Beauty Elixir distinguishes itself from other beautyfood products on the market with the preventative complex that protects skin from the inside out from environmental factors and prevents the signs of ageing. Moreover, the active complex activates the beauty process in the body, ensuring radiant beauty from head to toe - no matter the age of the person using it. The Elixir has a fruity-fresh taste and is free of sweeteners, artificial colours, lactose and gluten.
The direct sales method with trained, independent sales partners who introduce and sell products in a professional manner with a high consultation level, is crucial to the success of the product.
German Brand Award | German Design Council
The German Brand Award is a prize offered by the German Design Council and the German Brand Institute, crowning the most innovative brands, consistent branding, and sustainable brand communication. It is divided into two competitions: "Excellent Brands" awards the best product and company brands in an industry. "Excellence in Brand Strategy and Creation" honours the strongest campaigns, concepts and strategies in individual disciplines.
The German Design Council is an independent and internationally active institution that assists companies to efficiently communicate design and brand competence, while at the same time aiming to strengthen the general public's understanding of design. Established as a foundation in 1953, at the initiative of the German Bundestag by the Federation of German Industries and several leading companies, the German Design Council supports the advancement of design and branding with its competitions, exhibitions, conferences, seminars and publications. Currently, over 300 companies both inland and abroad belong to the circle of founders of the German Design Council. More information: german-brand-award.com
LR Health & Beauty
With its "More quality for your life" campaign, the LR Group, with headquarters in Ahlen, Westphalia, produces and markets various beauty and health products in 28 countries. The products include care and decorative cosmetics, dietary supplements and perfume. The processing of aloe vera has been one of LR Health & Beauty's key areas of expertise for over 15 years, whereby the precious inside of the leaf is exclusively used. With an annual volume of 12,000 tons of aloe vera leaves, today the company is one of the largest manufacturers of aloe vera products worldwide. With 1,100 employees and thousands of registered Sales Partners and clients, LR is one of the leading direct sales companies in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005247/en/
Contact:
LR Health & Beauty Almut Kellermeyer Head of PR / Public Affairs Tel.: +49 2382 7060-106 E-mail: A.Kellermeyer@LRworld.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom